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Summary In breast cancer patients. prognostic information required to plan post-surgical therapy is obtained
mainly through axillary dissection. This study was designed to establish a new prognostic score based solely on
parameters of the primary tumour as an alternative to axillary surgery in assessing prognosis. Eight different
prognostic factors, including menopausal status, tumour size. grading. lymphatic invasion. desmoplasia.
necrosis. c-erbB-2 and laminin receptor expression. were evaluated retrospectively on a large series of primary
breast carcinoma patients. From multivariate analysis, four independent parameters were selected and
examined. alone and in combination, for their prognostic potential. These parameters were used to generate a
prognostic score that was analysed retrospectively in 467 NO-Nla patients to determine its predictive value for
survival. The score. which includes variables such as tumour size, grading. laminin receptor and c-erbB-2
overexpression. was established based on the number of negative prognostic factors: score I refers to cases in
which all four parameters reflect a good prognosis, scores 2 and 3 refer to tumours in which, respectively, one
or two of the four parameters reflect a poor prognosis. whereas score 4 refers to tumours with three or four
poor prognosis factors. Analysis of the overall survival of the four score groups shows that patients with score
I tumours (22% of the total) had the best prognosis with a 15 year survival of 82%. patients with score 2 and
3 had an intermediate prognosis. whereas score 4 patients had the poorest prognosis with a 15 year survival of
only 38%o. Moreover. survival in the N' score 1 cases was found to be longer than that in the total N-
patients. Our data suggest that the primary tumour score provides more reliable prognostic information than
pathological nodal status. and that axillary dissection can be avoided in a large number of patients.
Post-surgical treatment of breast cancer patients is deter-
mined largely on the basis of pathological nodal status.
which is considered to be the most important prognostic
indicator of this disease. In the past, most tumours were
diagnosed at an advanced stage. with frequent nodal involve-
ment. so that axillary dissection was performed for both
prognostic and therapeutic purposes. However, with current
screening programmes for early breast carcinoma detection.
the frequency of patients presenting with nodal involvement
is considerably decreased. As a result. surgical intervention
on the axillae is performed primarily to obtain prognostic
information rather than to control regional disease (Fisher et
al.. 1985). In the absence of alternative prognostic factors,
nodal status remains critical in identifying patients who
require adjuvant systemic therapy. Thus, despite that recent
trend toward less invasive surgical intervention for the
pnmary tumour (Veronesi et al., 1990). the advantages of
breast conservative surgery are limited by axillary node
dissection, which is still routinely done.
The concept that tumour aggressiveness can be evaluated
not only by analysing parameters that measure a metastatic
event. such as nodal spread. but also by analysing intrinsic
biological factors displayed by the primary tumour, has been
widely investigated (Foekens et al.. 1991; Slamon. 1991:
Bosari et al.. 1992: Noguchi et al., 1992; Pavelic et al., 1992).
However, so far no single prognostic factor. such as
oncogenes. suppressor genes. enzymes or adhesion receptors,
has been found to be as potent a predictor as nodal status
(Slamon et al.. 1989; Rilke et al., 1991: Martignone et al..
1993). Unfortunately, nodal status in some cases fail to
correctly predict the prognosis: in fact. 30% of N- patients
relapse and 30% of N+ patients have a long survival (Galea
et al.. 1992).
In the present study. we describe a prognostic score based
only on parameters of the primary tumour that may avoid
the need for axillary dissection in clinically node-negative
patients. This score. evaluated retrospectively on 463 primary
breast carcinomas from patients without palpable no-des.
appears to provide more accurate prognostic information
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than does nodal status. In addition, the score was evaluated
in 350 Nlb patients in association with nodal status and it
was found to identify those patients in whom nodal status
failed to predict the correct prognosis.
Patets aindmhods
Patients
The study included 813 patients surgically treated at this
institute from 1968 to 1969 for infiltrating duct or lobular
breast carcinoma. Surgical treatment consisted of radical or
modified radical mastectomy and axillary dissection. Only
histologically node-positive patients received post-surgical
radiotherapy on supraclavicular and internal mammary
lymph nodes. No patient had adjuvant systemic therapy.
Perimenopausal patients were classified as premenopausal.
Histopathology
Tumour size and nodal infiltration were obtained from histo-
pathological reports. The grading procedure was performed
according to Bloom and Richardson (1957) and grades I and
II were considered together for the score evaluation.
Peritumoral lymphatic invasion, desmoplasia and necrosis
were evaluated as previously described (Rilke et al.. 1991).
Immunohistochemistrv
Paraffin sections were stained as previously descnrbed (Rilke
et al., 1991) using the avidin-biotin-peroxidase method and
antibodies directed against the c-erbB-2 oncoprotein (Slamon
et al., 1989) or the laminin receptor (Martignone et al., 1992).
Sections were considered positive when more than 10% of
the tumour cells were labelled.
Statistical analtsis
Overall survival of patients from the date of surgical treat-
ment was considered as the end point of this study. Only
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deaths due to breast carcinoma were considered as events.
whereas deaths due to other causes were estimated as with-
drawals. Survival rates were calculated using the actuarial life
table method considering the subgroups identified by the
variables examined. Survival curves were compared using the
log-rank test. Multivariate analysis was carried out using the
Cox regression model; the relative frequency of each variable
tested was evaluated by the step-down procedure for variable
selection at a 5% significance level.
survival rates of these 90 patients. divided according to score,
were similar to those reported for the NO-Nla series,
although the small sample size precluded statistical evalua-
tion (data not shown). By contrast, the remaining 260 Nlb
N+ patients (Table III) showed a decrease in survival pro-
bability in the different score categories compared with the
same score cases of the NO-Nla, N+ group (Table II).
Disa nio
Results
The impact of each of eight factors on survival was evaluated
on a series of 463 primary breast carcinomas obtained from
patients without palpable lymph nodes (Table I). Multi-
variate analysis indicated that four of these factors, namely
tumour size. grading, c-erbB-2 oncogene overexpression and
laminin receptor overexpression. independently predict the
outcome of the disease.
These four factors were analysed together in order to
obtain a prognostic score based on the number of negative
prognostic variables. Score 1 refers to cases in which the four
parameters reflect a good prognosis: small tumours of grade
1 or 2 and no amplified expression of c-erbB-2 or laminin
receptor. Scores 2 and 3 refer to tumours with one or two
high-risk parameters, respectively, and score 4 indicates
tumours with three or four poor prognosis indicators.
The overall survival of the score groups was evaluated in
two ways. First, scores 1 and 2 (score A) and scores 3 and 4
(score B) were each considered together for direct com-
parison with the N- and N+ groups. The survival rates in
these two score categories (Figure la) indicated that patients
with low scores survived longer than did N- patients, and
patients with high scores had poorer survival than did the
N+ group. The four score groups were also evaluated
separately. The survival curves (Figure lb), which differ
significantly (P<0.01). show that the 101 patients with a
score 1 tumour had a 15 year survival of 82% (95% CI
90-74%), the 157 patients with score 2 and the 136 patients
with score 3 tumours had intermediate prognoses (60%. 95%
CI 68-52%. and 51%. 95% CI 59-44%, respectively).
whereas the 15 year survival of score 4 patients was only
38% (95% CI 50-26%). The survival curves of the N- and
N+ patients were similar to those of the score 2 and score 3
patients respectively. Survival rates of the same patients were
evaluated within each of the four score groups according to
pathological lymph node status (Table II). Score 1 patients
were more frequently N-. whereas score 4 patients were
more frequently N+. These differences were statistically
significant as determined using the for trend' test
(P = 0.01). The survival rate of N+ score 1 patients was still
higher than that of the total N- group. Even in the other
groups, the score gave more prognostic information than the
nodal status; indeed, the N+ score 2 and N+ score 3 patients
showed survival rates similar to those of N- score 3 and N-
score 4 groups respectively.
The score was evaluated in 350 Nlb patients, including 90
patients (26%) who were pathologically node negative. The
Table I Prognostic factors evaluated on primary breast
carcinomas
Impact on survival
Lnivariate Multivariate
Parameter Per cent P-value P-value
Premenopausal status 33 10-3 NS
Tumour size (>2cm) 32 2 x 10-6 4 x 10-4
Grading (3) 42 3 x 10-4 1lo-
Peritumoral lymphatic invasion 25 NS
Desmoplasia 65 NS
Necrosis 10 NS
c-erbB-2 overexpression 23 7 x 10-4 5 x 10-'
Laminin receptor expression 44 2 x 10-' 10-'
NS. not significant.
In the present study. we have described an alternative ap-
proach to axillary dissection in assessing prognosis of post-
surgery breast cancer patients without palpable lymph nodes.
This approach relies on four parameters of the primary
tumour, two of which are important pathological parameters,
namely grading and tumour size (Carter et al., 1989; Elston
& Ellis, 1991), and two of which are biological parameters
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Figure 1 a, Survival of breast cancer patients grouped according
to pathological node status or combined (score A = 1 + 2; score
B = 3 + 4) scores: 258 score A (A), 205 score B (V) or 251 N-
(U) and 212 N+ (v) patients, b. Survival of breast cancer
patients in four separate score groups: 101 score I (-). 157 score
2 (0), 136 score 3 (A) and 69 score 4 (V) patients.
Table II Relevance of pathological nodal status according to the
prognostic score in NO-NIa patients
Prognostic Nodal No. of casee Survival (%) after
score status (% INV) 5 iears 10 sears 15 sears
1 - 65 95 89 85
+ 36 (36)* 94 85 76
2 - 83 84 77 64
+ 74 (47)* 78 62 51
3 - 72 70 58 54
+ 64 (47)* 67 49 41
4 - 31 76 54 45
+ 38 (55)* 49 41 32
Total - 251 82 71 64
+ 212 (46) 69 57 49
'Pathological. *r=6.78. P = 0.07: y for trend= 5.50. P = 0.01.
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Table In Relevance of the prognostic score in Nib. N'
patients
Prognostic No. of Survival (%) after
score cases (%} 5 Years 10 Years 15 sears
1 31 (12) 80 67 48
2 73 (28) 65 56 51
3 85 (33) 47 32 29
4 71 (27) 35 29 29
Total 260 53 42 36
associated with tumour aggressiveness owing to their sug-
gested role in tumour growth (Lupu et al., 1992) and metas-
tatic spread (Castronovo et al., 1990).
The use of our primary tumour score allows a more
accurate grouping of patients with different prognoses com-
pared with pathological nodal status evaluation. Indeed.
patients classified as score I had a very good prognosis
independent of nodal status, since survival in even the N+
cases in this group was longer than that in the entire series of
N- patients. Although one might argue that early removal of
clinically negative but pathologically positive nodes would
favourably affect survival of these patients, several studies
have shown that survival rates are similar whether axillary
nodes are removed at the time of primary tumour surgery or
when the nodes became palpable (Lythgoe et al., 1978; Fisher
et al., 1981, 1983; Fisher. 1985). Therefore, in these score 1
patients. axillary dissection is unnecessary. In the other score
groups, nodal status is also irrelevant since, even according
to the scores, these patients in any case require adjuvant
treatment. Together, these data suggest that surgical treat-
ment in a large number of breast cancer patients can be
restricted to the primary tumour and that the score evalua-
tion can reliably replace node examination. In fact, axillary
dissection can be safely limited to the minority of clinically
node-negative patients who develop overt axillary metastases.
A recent report (Haffty et al., 1990) suggests that regional
nodal irradiation should be used to control the disease at the
axillary level.
In the NIb series, the score identified the small number of
patients with a good prognosis for whom adjuvant therapy
should be an overtreatment. such as the 18 score I N-
patients. For all of the other patients considered together,
including the score 1 N+ patients, the prognosis was similar
or worse than the total N+ series. Moreover, the particularly
unfavourable prognosis of score 3 and 4,N+ patients suggests
that a course of intensified adjuvant treatment would be
beneficial.
In the patient series considered in this study. tumours were
surgically removed when early diagnostic procedures were
not available, and more than 50% of such patients were node
positive. It is likely that more early-stage tumours will be
detected by current screening programmes. and often these
will be node negative, frequently with a low score. This
further emphasises the clinical importance of the availability
of a prognostic score than can correctly identify patients in
whom surgery can be safely limited.
Previous efforts to construct prognostic indexes based on
different prognostic factors have all included the nodal status
as a variable, with the goal of distinguishing patients who
require adjuvant therapy (Blamey et al., 1979; Haybittle et
al.. 1982; Aaltomaa et al., 1991; Kallioniemi et al.. 1991:
Galea et al., 1992). Our focus has been on assessing prog-
nosis without considering nodal status in order to limit sur-
gical intervention and plan appropriate therapy. Other
biological indicators relevant in disease progression (Cat-
toretti et al., 1988; Rochefort et al.. 1990; Callahan, 1992).
might be used as alternatives or adjuncts to laminin receptor
or c-erbB-2 oncoprotein overexpression if they increase the
prognostic potential of the score. However. additional
parameters should be amenable to evaluation by immunohis-
tochemistry or similar methods that are simple. rapid and
economical to ensure the feasibility of the score evaluation.
even for small tumours. in all types of institutions.
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